10-Q: Alzamend Neuro Reports Q3 2025 Financial Results, Cites Progress in Clinical Trials and Financing Activities

Alzamend Neuro announces its financial results for the third quarter of fiscal year 2025, highlighting ongoing clinical trials for AL001 and ALZN002, and recent financing activities to support operations.

Summary

• Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, has released its financial results for the quarter ended January 31, 2025.
• The company is focused on developing novel products for the treatment of Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
• Alzamend's pipeline includes two drug candidates: AL001, an ionic cocrystal technology, and ALZN002, a cell-based therapeutic vaccine.
• The company reported a net loss of $1.039 million for the three months ended January 31, 2025, compared to a net loss of $2.662 million for the same period in 2024.
• Research and development expenses decreased to $447,111 from $1.908 million year-over-year, primarily due to reduced clinical trial activities.
• General and administrative expenses also decreased to $590,304 from $751,173 year-over-year.
• For the nine months ended January 31, 2025, the net loss was $3.375 million, compared to $9.096 million for the same period in 2024.
• The company's cash position as of January 31, 2025, was $3.358 million, with working capital of $3.2 million.
• Alzamend has been financing its operations through equity and debt instruments and expects to continue incurring net losses in the foreseeable future.
• The company is actively pursuing additional financing through at-the-market offerings and sales of preferred stock.
• Subsequent to the quarter, Alzamend entered into a securities purchase & exchange agreement with Orchid for the exchange of Series A Convertible Preferred Stock for Series C Convertible Preferred Stock and the purchase of additional Series C Convertible Preferred Stock and warrants.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials and has secured additional financing, it continues to incur net losses and faces challenges related to its cash position and internal controls. The future success of the company is highly dependent on its ability to successfully develop and commercialize its product candidates.

Positives

• Net loss decreased significantly for both the three and nine months ended January 31, 2025, compared to the same periods in 2024.
• Research and development expenses decreased, indicating potential cost management or a shift in research focus.
• The company's cash position improved substantially, providing more financial flexibility.
• Alzamend is actively advancing its clinical development programs for AL001 and ALZN002.
• The company has secured additional financing through at-the-market offerings and preferred stock sales.

Negatives

• The company continues to incur net losses and expects to do so for the foreseeable future.
• Management believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial statements are issued.
• The company has a significant accumulated deficit of $57.4 million as of January 31, 2025.
• The company identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt.
• Alzamend needs to raise additional capital to fund its operations and clinical development activities.
• The company's success depends on the successful development and commercialization of its product candidates, which is subject to regulatory approval and market acceptance.
• The company faces competition from other pharmaceutical companies developing treatments for Alzheimer's disease and related disorders.
• The company identified material weaknesses in its internal control over financial reporting.

Future Outlook

Management believes that the company's cash and cash equivalents at January 31, 2025, together with the anticipated receipt of funds from its at-the-market offering and from the sale of its Series A and Series B Convertible Preferred Stock pursuant to the securities purchase agreements related thereto, will be sufficient to meet the company's anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.

Management Comments

• Management believes its current cash on hand is not sufficient to fund its planned operations through one year after the date the condensed financial statements are issued.
• Management continues to work to improve its controls related to our material weaknesses, specifically relating to user access and change management surrounding our information technology systems and applications.

Industry Context

Alzamend is operating in the competitive biopharmaceutical industry, specifically targeting Alzheimer's disease and related disorders. The company's focus on novel therapeutic approaches, such as ionic cocrystal technology and cell-based therapeutic vaccines, positions it to potentially address unmet needs in the treatment of these conditions. The company's success will depend on its ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy.

Comparison to Industry Standards

• It's difficult to directly compare Alzamend's financial results to industry standards without knowing the specific stage of development and therapeutic focus of comparable companies.
• However, the decrease in R&D expenses could be compared to other clinical-stage biopharmaceutical companies that have completed Phase II trials and are preparing for Phase III trials, as they may experience a similar decrease in R&D spending.
• The company's reliance on equity financing is common among early-stage biopharmaceutical companies, but it's important to assess the terms of these financings and their potential impact on existing shareholders.
• Companies like AC Immune SA and Cassava Sciences, Inc. are also focused on Alzheimer's disease and could be considered peers, but their financial situations and clinical progress may vary significantly.

Related Party Transactions

• In connection with the Old Orchid SPA, the Company agreed to pay Ault Lending an origination fee of five percent (5%) of the total gross proceeds we receive from Orchid upon each purchase of Series A Convertible Preferred Stock.
• During the nine months ended January 31, 2025, origination fees due to Ault Lending were $ 400,000 .

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will directly impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs will affect job security and opportunities for growth.
• Patients: The successful development of AL001 and ALZN002 could provide new treatment options for Alzheimer's disease and related disorders.
• Creditors: The company's ability to repay its debts depends on its financial performance and access to capital.

Next Steps

• Continue clinical development of AL001 for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD treatment.
• Continue clinical development of ALZN002 for Alzheimer's treatment.
• Hold a meeting of our stockholders within 90 days of the execution date of the New Orchid SPA for purposes of seeking stockholder approval of the issuance of all the shares of common stock issuable upon conversion of the Series C Convertible Preferred Stock and the exercise of the warrants in excess of the Nasdaq Limit.

Key Dates